Core Viewpoint - The AI-driven drug discovery and development company Insilico Medicine (3696.HK) experienced a significant stock increase of 14%, reaching HKD 68.7, with a market capitalization approaching HKD 40 billion following the announcement of a milestone payment from Menarini Group for the MEN2501 project [1] Company Summary - Insilico Medicine has authorized the MEN2501 project to Menarini Group, which has successfully completed the first patient dosing in Phase I clinical trials [1] - The company received a milestone payment of approximately HKD 39 million from Menarini as part of their collaboration agreement [1] - MEN2501, previously known as ISM9682, is a highly differentiated small molecule inhibitor targeting the driver protein KIF18A, showing significant inhibitory activity against chromosomal instability cancers in preclinical data [1]
港股异动丨英矽智能大涨14%创新高 获美纳里尼3900万港元里程碑付款